Improving treatment for pediatric brain tumors with BRAF mutations
Enhancing MAPK-targeted Therapy in PDX Models of BRAF-Mutant Pediatric Brain Tumors
This study is looking at new ways to help kids with brain tumors caused by a specific gene mutation, using special models to test how well certain medications work and to find better treatments for these tough cancers.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Texas Hlth Science Center NIH-funded |
| Lab location | 1 site (San Antonio, United States) |
| Project ID | NIH-11031311 on NIH RePORTER |
What this research studies
This research focuses on enhancing therapies for pediatric brain tumors that are driven by mutations in the BRAF gene, particularly the V600E mutation. It utilizes patient-derived xenograft (PDX) models to investigate the effectiveness of MEK inhibitors, which have shown promise in treating these tumors. The goal is to understand how to overcome resistance to current treatments and improve outcomes for young patients suffering from these aggressive cancers. By building on previous clinical trial results, this research aims to pave the way for new clinical trials that could lead to better treatment options.
Who could benefit from this research
Good fit: Ideal candidates for this research are children aged 0-11 years diagnosed with BRAF-mutant brain tumors.
Not a fit: Patients with brain tumors that do not have BRAF mutations may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for children with BRAF-mutant brain tumors, potentially improving survival rates and quality of life.
How similar studies have performed: Previous studies have shown success with MEK inhibitors in treating similar pediatric brain tumors, indicating a promising avenue for further exploration.
Where this research is happening
San Antonio, United States
- University of Texas Hlth Science Center — San Antonio, United States (Active)
Researchers
- Principal investigator: Burma, Sandeep — University of Texas Hlth Science Center
- Study coordinator: Burma, Sandeep
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.